| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurosurgery (Drs. Takayama, Miyamoto, Mikuni, Takahashi, Satow, and Hashimoto), Human Brain Research Center (Drs. Takayama, Usui, Satow, Yamamoto, Matsuhashi, Nagamine, and Shibasaki), and Department of Neurology (Drs. Ikeda, Matsumoto, and Shibasaki), Kyoto University Graduate School of Medicine, Kyoto, Japan.
Address correspondence and reprint requests to Dr. Susumu Miyamoto, Department of Neurosurgery, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan; e-mail: miy{at}hsp.ncvc.go.jp
Objective: To evaluate the usefulness of propofol as an alternative drug to amobarbital for the Wada test.
Methods: The authors analyzed 67 right-handed patients out of 123 patients who were candidates for neurosurgical therapy and thus underwent the Wada test as a preoperative evaluation. Twelve were tested with propofol and 55 were tested with amobarbital. Test conditions of the Wada test, recovery time of muscle power to manual muscle testing (MMT) Grade 3 (T3/5) and Grade 5 (T5/5), onset time of the first verbal response (Tverb) after injection and that of the first nonverbal response (Tnon-verb), were compared between the two groups. Power spectrum analysis of EEG background activity during the Wada test was performed and the time and spatial distribution of polymorphic slow activities were also compared in three cases.
Results: With propofol injection, lateralities of language and memory function were identified in 12 and 9 of 12 patients in comparison to amobarbital (52 and 41 of 55 patients detection in language and memory function). No complications with direct intracarotid injection of propofol were observed. T3/5 and T5/5 with propofol injection were shorter while Tverb and Tnon-verb were longer compared to amobarbital. Absolute power of polymorphic slow EEG waves gradually increased and then rapidly decreased with propofol, which was in contrast to amobarbital injection.
Conclusions: With direct intracarotid propofol injection, the Wada test was satisfactorily performed in all 12 patients and 2 more patients with left-handedness or with different injection dose for each side without any complications. Clinical usefulness of propofol as an alternative drug to amobarbital for the Wada test was indicated.
Received August 18, 2003. Accepted in final form March 31, 2004.
This article has been cited by other articles:
|
|
 |
|
  S. Joshi, M. Wang, J. J. Etu, and J. Pile-Spellman Bolus configuration affects dose requirements of intracarotid propofol for electroencephalographic silence. Anesth. Analg., June 1, 2006; 102(6): 1816 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Grote and K. Meador Has amobarbital expired?: Considering the future of the Wada Neurology, December 13, 2005; 65(11): 1692 - 1693. [Full Text] [PDF]
|
|
|
|
|
|
M. Jones-Gotman, V. Sziklas, J. Djordjevic, F. Dubeau, J. Gotman, M. Angle, D. Tampieri, A. Olivier, and F. Andermann Etomidate speech and memory test (eSAM): A new drug and improved intracarotid procedure Neurology, December 13, 2005; 65(11): 1723 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mikuni, M. Takayama, T. Satow, S. Yamada, N. Hayashi, N. Nishida, J. Taki, R. Enatsu, A. Ikeda, S. Miyamoto, et al. Evaluation of adverse effects in intracarotid propofol injection for Wada test Neurology, December 13, 2005; 65(11): 1813 - 1816. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
